PIK3CA and neoplasm: All of them were found to be PIK3CA mutated at the time of progression; each patient’s specific mutations were followed in the different circulating biomarkers in comparison with the corresponding tumor tissue (details in Table 2 and Table 3, Figure 1 and Figure 2).